We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
Read MoreHide Full Article
Mirum Pharmaceuticals (MIRM - Free Report) incurred a loss of 49 cents per share in fourth-quarter 2024, much wider than the Zacks Consensus Estimate of a loss of 27 cents. The company had reported a loss of 66 cents per share in the year-ago quarter.
Revenues in the fourth quarter totaled $99.4 million, up 42.8% year over year. The figure also beat the Zacks Consensus Estimate of $97 million. The top line comprised sales of Livmarli (maralixibat) and newly acquired products, Cholbam and Chenodal.
Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe.
Mirum acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and chenodiol tablets to its portfolio of commercialized drugs.
In the past year, shares of Mirum have rallied 70.3% against the industry’s decline of 9.5%.
Image Source: Zacks Investment Research
More on MIRM's Q4 Results
During the fourth quarter, the company recorded minimal negative license and other revenues. It did not record any such revenues in the year-ago quarter.
Research and development expenses increased 42.4% year over year to $44 million.
Selling, general and administrative expenses totaled $56.8 million, up almost 22.9% from the year-ago quarter’s level.
As of Dec 31, 2024, Mirum had cash, cash equivalents and marketable securities worth $292.8 million compared with $293.8 million as of Sept. 30, 2024.
MIRM's Full-Year Results
For 2024, Mirum generated revenues of $336.9 million compared with $186.4 million recorded in the year-ago quarter.
For the same period, the company reported a loss of $1.85 per share, narrower than a loss of $4.00 per share in the year-ago period.
2025 Guidance
Mirum expects worldwide net product sales of approximately $420-$435 million and positive cash flow in 2025.
MIRM's Recent Updates
Mirum is evaluating Livmarli in the phase III EXPAND study for treating pruritus in rare cholestatic conditions. Enrollment in the study is expected to be completed in 2026.
Earlier this week, the FDA approved Ctexli (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Following the nod, Ctexli became the first and only treatment to be approved for this rare, progressive and debilitating disease.
Mirum’s lead pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study).
Enrollment in the VISTAS study is expected to be completed in the second half of 2025 with top-line data expected to be announced in 2026. The company expects to complete enrollment in the VANTAGE study in 2026.
Mirum also plans to initiate a phase II study on its recently in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome later in 2025.
Mirum Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for Rigel Pharmaceuticals’ earnings per share have increased from 92 cents to $1.28 for 2025. In the past year, shares of RIGL have risen 44.1%.
RIGL earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 1,754.28%.
In the past 60 days, estimates for argenx’s earnings per share have increased from $9.08 to $10.85 for 2025. In the past year, shares of ARGX have risen 56.5%.
ARGX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 339.37%.
In the past 60 days, estimates for Pacira BioSciences’ earnings per share have increased from $2.79 to $3.59 for 2025. In the past year, shares of PCRX have decreased 14.9%.
PCRX’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 7.13%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
Mirum Pharmaceuticals (MIRM - Free Report) incurred a loss of 49 cents per share in fourth-quarter 2024, much wider than the Zacks Consensus Estimate of a loss of 27 cents. The company had reported a loss of 66 cents per share in the year-ago quarter.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Revenues in the fourth quarter totaled $99.4 million, up 42.8% year over year. The figure also beat the Zacks Consensus Estimate of $97 million. The top line comprised sales of Livmarli (maralixibat) and newly acquired products, Cholbam and Chenodal.
Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe.
Mirum acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and chenodiol tablets to its portfolio of commercialized drugs.
In the past year, shares of Mirum have rallied 70.3% against the industry’s decline of 9.5%.
Image Source: Zacks Investment Research
More on MIRM's Q4 Results
During the fourth quarter, the company recorded minimal negative license and other revenues. It did not record any such revenues in the year-ago quarter.
Research and development expenses increased 42.4% year over year to $44 million.
Selling, general and administrative expenses totaled $56.8 million, up almost 22.9% from the year-ago quarter’s level.
As of Dec 31, 2024, Mirum had cash, cash equivalents and marketable securities worth $292.8 million compared with $293.8 million as of Sept. 30, 2024.
MIRM's Full-Year Results
For 2024, Mirum generated revenues of $336.9 million compared with $186.4 million recorded in the year-ago quarter.
For the same period, the company reported a loss of $1.85 per share, narrower than a loss of $4.00 per share in the year-ago period.
2025 Guidance
Mirum expects worldwide net product sales of approximately $420-$435 million and positive cash flow in 2025.
MIRM's Recent Updates
Mirum is evaluating Livmarli in the phase III EXPAND study for treating pruritus in rare cholestatic conditions. Enrollment in the study is expected to be completed in 2026.
Earlier this week, the FDA approved Ctexli (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Following the nod, Ctexli became the first and only treatment to be approved for this rare, progressive and debilitating disease.
Mirum’s lead pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study).
Enrollment in the VISTAS study is expected to be completed in the second half of 2025 with top-line data expected to be announced in 2026. The company expects to complete enrollment in the VANTAGE study in 2026.
Mirum also plans to initiate a phase II study on its recently in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome later in 2025.
Mirum Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Mirum Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Mirum Pharmaceuticals, Inc. Quote
MIRM's Zacks Rank & Other Stocks to Consider
Mirum currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the drug/biotech sector are Rigel Pharmaceuticals, Inc. (RIGL - Free Report) , argenx SE (ARGX - Free Report) and Pacira BioSciences, Inc. (PCRX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Rigel Pharmaceuticals’ earnings per share have increased from 92 cents to $1.28 for 2025. In the past year, shares of RIGL have risen 44.1%.
RIGL earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 1,754.28%.
In the past 60 days, estimates for argenx’s earnings per share have increased from $9.08 to $10.85 for 2025. In the past year, shares of ARGX have risen 56.5%.
ARGX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 339.37%.
In the past 60 days, estimates for Pacira BioSciences’ earnings per share have increased from $2.79 to $3.59 for 2025. In the past year, shares of PCRX have decreased 14.9%.
PCRX’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 7.13%.